Therapy News and Research

RSS

Uterine health is more relevant for fetus to achieve normal birth weight, full gestation

For women seeking pregnancy by assisted reproductive technologies, such as in-vitro fertilization, a new study shows that the health of the uterus is more relevant than egg quality for a newborn to achieve normal birth weight and full gestation.

2 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

FDA approves FSS's FlexStent system IDE for OPEN Trial

Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.

2 Feb 2011

Damaged heart rebuilt with heart stem cells from children with congenital heart disease

A new study, revealing that heart stem cells from children with congenital heart disease were able to rebuild the damaged heart in the laboratory, could provide a new outlet for Emerging Healthcare Solutions' NASA bioreactor.

2 Feb 2011

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.

2 Feb 2011

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.

2 Feb 2011

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net sales and earnings per share (EPS) guidance for the full year and first quarter 2011.

2 Feb 2011

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

A new evidence report by ECRI Institute comparing the effectiveness of various treatments for bulimia nervosa indicates that cognitive behavioral therapy is more effective than antidepressant medications and supportive therapies in improving eating disorder symptoms.

2 Feb 2011

New study examines role of later acquisition of hepatitis C in HIV patients

Hepatitis C is a leading cause of illness and death for individuals infected with both HIV and hepatitis C. Recent reports from around the world demonstrate that hepatitis C is emerging as a sexually transmitted infection among HIV-infected men who do not inject drugs. However, many HIV-infected men do not receive continued screening for hepatitis C throughout their HIV care.

2 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Four new fact sheets address impact of combat injury on intimacy

The impact of combat injury on intimacy is an important and often neglected aspect of healthcare communication. Four new fact sheets addressing the impact of the injuries of war, both physical and psychological, on intimacy have just been released for healthcare providers and affected military families.

2 Feb 2011

Masimo PVI predicts fluid responsiveness with high sensitivity, specificity in ICU patients

Masimo announced today that a new study published in the peer-reviewed journal Critical Care Medicine demonstrates that noninvasive, continuous monitoring of Masimo Pleth Variability Index predicts fluid responsiveness with high sensitivity and specificity in mechanically-ventilated patients in the Intensive Care Unit.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

$Researchers find breast cancer therapy contributes to early-in-life hip fractures in women$

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

A hip fracture is not common in a 54-year-old woman, unless she is a 54-year-old breast cancer survivor, according to a new Northwestern Medicine study. Researchers found that a combination of early menopause due to breast cancer treatment and common drugs used to treat breast cancer, could be weakening the bones of breast cancer survivors once they hit middle age, leading to hip fractures.

2 Feb 2011

New robotic technique can better predict tumors during radiotherapy, prevent severity of side effects

Medical physicists at Thomas Jefferson University and Jefferson's Kimmel Cancer Center have demonstrated a new real-time tumor tracking technique that can help minimize the amount of radiation delivered to surrounding healthy tissue in a patient—up to 50 percent less in some cases—and maximize the dose the tumor receives.

2 Feb 2011

Study finds treatment-related mortality with bevacizumab in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab may be at an increased risk of treatment-related death when the drug is used in combination with other therapies.

2 Feb 2011

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.

2 Feb 2011

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Today Quebec is providing access to a therapy in a new class of osteoporosis treatments. With Quebec being the first province to list Prolia on public and private drug plans, Canadians living with osteoporosis in the province of Quebec now have access to increased treatment options.

2 Feb 2011

Scientists discover breast cancer cells that dodge immune system, promote tumor growth

Scientists discovered a new way breast cancer cells dodge the immune system and promote tumor growth, providing a fresh treatment target in the fight against the disease. While comparable mechanisms to avoid the immune system have been identified in mice with breast and other cancers, the study tested human breast tumor cells, putting researchers closer to understanding how the disease progresses in real patients.

2 Feb 2011

Therapy News and Research

Uterine health is more relevant for fetus to achieve normal birth weight, full gestation

Researchers discover potential vaccine capable of reducing H. pylori colonization

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

FDA approves FSS's FlexStent system IDE for OPEN Trial

Damaged heart rebuilt with heart stem cells from children with congenital heart disease

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

New study examines role of later acquisition of hepatitis C in HIV patients

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Four new fact sheets address impact of combat injury on intimacy

Masimo PVI predicts fluid responsiveness with high sensitivity, specificity in ICU patients

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

New robotic technique can better predict tumors during radiotherapy, prevent severity of side effects

Study finds treatment-related mortality with bevacizumab in cancer patients

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Scientists discover breast cancer cells that dodge immune system, promote tumor growth

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News